Findings published recently in BMC Cancer suggest the FDA-approved drug dronabinol, which is a synthetic version of THC, kills leukemia cells and offers cancer patients a "low-toxic therapy option." In the study, German researchers looked at the impact of dronabinol on leukemia cells, and reported the drug displayed "remarkable anti-proliferative as well as pro-apoptopic efficacy... in a broad spectrum of acute leukemia cell lines." They went on to say that these results "provide a promising rationale for the clinical use of cannabinoids... in distinct entities of acute leukemia."
This information is consistent with other studies that have produced similar positive results when it comes to the impact of various cannabinoids on cancer progression and cancer cell death. This information has been brought to you by The Daily Chronic and approved by our Chief Medical Officer.